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Abstract. The circulating concentrations of triglycerides, 
high density lipoprotein (HdL)-cholesterol, and low density 
lipoprotein (LdL)-cholesterol have a substantial genetic 
component, and the heritability of early-onset dyslipidemia 
might be expected to be higher compared with late-onset 
forms. In the present study, exome-wide association studies 
(EWASs) were performed for early-onset hypertriglyceridemia, 
hypo-HdL-cholesterolemia, and hyper-LdL-cholesterolemia, 
with the aim to identify genetic variants that confer suscep-
tibility to these conditions in the Japanese population. A 
total of 8,073 individuals aged ≤65 years were enrolled in 
the study. The EWASs for hypertriglyceridemia (2,664 cases 
and 5,294 controls), hypo-HdL-cholesterolemia (974 cases 
and 7,085 controls), and hyper-LdL-cholesterolemia 
(2,911 cases and 5,111 controls) were performed with 
Illumina Human Exome-12 v1.2 dNA Analysis Beadchip 
or Infinium Exome‑24 v1.0 BeadChip arrays. The associa-
tion of allele frequencies for 31,198, 31,133, or 31,175 single 
nucleotide polymorphisms (SNPs) to hypertriglyceridemia, 
hypo-HdL-cholesterolemia, or hyper-LdL-cholesterolemia, 
respectively, was examined with Fisher's exact test. To 
compensate for multiple comparisons of genotypes with each 
of the three conditions, Bonferroni's correction was applied 
for statistical significance of association. The results demon-
strated that 25, 28 and 65 SNPs were significantly associated 
with hypertriglyceridemia, hypo-HdL-cholesterolemia and 
hyper-LdL-cholesterolemia, respectively. Multivariable 
logistic regression analysis with adjustment for age and sex 
revealed that all 25, 28 and 65 of these SNPs were significantly 
associated with hypertriglyceridemia, hypo-HdL-cholesterol-
emia and hyper-LdL-cholesterolemia, respectively. Following 
examination of the association of the identified SNPs to 
serum concentrations of triglycerides, HdL-cholesterol, or 
LdL-cholesterol, linkage disequilibrium of the SNPs, and 
results of previous genome-wide association studies, we 
newly identified chromosomal region 19p12 as a susceptibility 
locus for hypertriglyceridemia, eight loci (MOB3C‑TMOD4, 
LPGAT1, EHD3, COL6A3, ZNF860‑CACNA1D, COL6A5, 
DCLRE1C, ZNF77) for hypo-HdL-cholesterolemia, and 
three loci (KIAA0319‑FAM65B, UBD, LOC105375015) for 
hyper-LdL-cholesterolemia. The present study thus identi-
fied 12 novel loci that may confer susceptibility to early‑onset 
dyslipidemia. determination of genotypes for the SNPs at 
these loci may prove informative for assessment of genetic 
risk for hypertriglyceridemia, hypo-HdL-cholesterolemia, or 
hyper-LdL-cholesterolemia in the Japanese population.
Introduction
dyslipidemia, including hypertriglyceridemia, hypo-high 
density lipoprotein (HdL)-cholesterolemia and hyper-low 
density lipoprotein (LdL)-cholesterolemia, has a substantial 
genetic component (1-3). Familial hypercholesterolemia is an 
autosomal dominant disorder characterized by pronounced 
increases in the circulating concentrations of total cholesterol 
and LdL-cholesterol (1,2). One of the underlying causes 
of familial hypercholesterolemia is a defect in the LdL 
receptor that is responsible for the uptake of most circulating 
LdL-cholesterol by the liver (2,4). In addition to mutations 
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of the LdL receptor gene (LDLR), familial hypercholester-
olemia can be caused by mutations in the apolipoprotein B 
gene (APOB), proprotein convertase subtilisin/kexin type 
9 gene (PCSK9), cytochrome P450 family 7 subfamily A 
member 1 gene (CYP7A1), and LdL receptor adaptor protein 
1 gene (LDLRAP1) (2,4). common forms of dyslipidemia 
are multifactorial and polygenic disorders, that result from 
an interaction between genetic background and both lifestyle 
and environmental factors, such as consumption of high-fat or 
high-calorie diets and physical inactivity (1,5). The heritability 
of plasma concentrations of triglycerides, HdL-cholesterol, or 
LdL-cholesterol was demonstrated to be 33-43, 40-74, and 
41‑59%, respectively (6‑8). Given that dyslipidemia is a key risk 
factor for coronary artery disease and ischemic stroke (9,10), 
as well as for colorectal cancer (11,12), personalized preven-
tion is an important public health goal.
Genome-wide association studies (GWASs) and 
gene-centric meta-analyses have implicated various genes and 
loci as determinants of blood lipid levels or of predisposition 
to dyslipidemia in European-ancestry populations (13-17). 
Genetic variants associated with lipid profiles have been exten-
sively investigated, with one recent study having identified 157 
such loci, including 62 variants not previously reported (18). 
Recent GWASs (19,20) or studies based on whole-exome (21) 
or whole-genome (22) sequencing in European-ancestry 
populations have also identified low‑frequency or rare vari-
ants associated with circulating lipid levels. A more recent 
exome‑wide association study (EWAS) identified 444 inde-
pendent variants at 250 loci as being significantly associated 
with plasma levels of total cholesterol, LdL-cholesterol, 
HdL-cholesterol, or triglycerides (23). An electronic health 
record-based study reported that genetic risk scores for 
circulating LdL-cholesterol and triglyceride levels based on 
477 single nucleotide polymorphisms (SNPs) were predictive 
of age at initiation of treatment with lipid-lowering medica-
tion (24). Although various SNPs have been demonstrated to 
be associated with blood lipid profiles in East Asian (25,26) or 
Japanese (27) populations, genetic variants that contribute to 
susceptibility to dyslipidemia in Japanese remain to be identi-
fied definitively.
Given the substantial genetic component of the circu-
lating concentrations of triglycerides, HdL-cholesterol, and 
LDL‑cholesterol (6‑8), the genetic contribution to early‑onset 
forms of hypertriglyceridemia, hypo-HdL-cholesterolemia, 
and hyper-LdL-cholesterolemia may be greater compared 
with late-onset forms (2,3). The statistical power of genetic 
association studies may thus be increased by focusing on 
subjects with early-onset forms of these disorders.
The present study performed EWASs for early-onset forms 
of hypertriglyceridemia, hypo-HdL-cholesterolemia, and 
hyper-LdL-cholesterolemia with the use of human exome 
array-based genotyping methods. The aim was to identify 
genetic variants that confer susceptibility to these conditions 
in the Japanese population.
Materials and methods
Study subjects. In our previous studies, the median age of 
subjects with hypertriglyceridemia, hypo-HdL-cholesterol-
emia or hyper‑LDL‑cholesterolemia was 64, 68 or 62 years, 
respectively (28). Therefore, in the present study, early-onset 
dyslipidemia was defined as that occurring at an age of 
≤65 years. A total of 8,073 individuals aged ≤65 years 
were examined. Recruited subjects either visited outpatient 
clinics or were admitted to participating hospitals in Japan 
(Gifu Prefectural Tajimi Hospital, Tajimi; Gifu Prefectural 
General Medical center, Gifu; Japanese Red cross Nagoya 
First Hospital, Nagoya; Northern Mie Medical center Inabe 
General Hospital, Inabe; Hirosaki University Hospital and 
Hirosaki Stroke and Rehabilitation center, Hirosaki) because 
of various symptoms or for an annual health checkup between 
2002 and 2014, or were community-dwelling individuals 
recruited to a population-based cohort study in Inabe between 
2010 and 2014 (29).
Venous blood was collected in the early morning after 
subjects had fasted overnight. The blood samples were centri-
fuged at 1,600 x g for 15 min at 4˚C, and serum was separated 
for subsequent analysis. Serum concentrations of triglycerides, 
HdL-cholesterol, and LdL-cholesterol were measured in the 
clinical laboratory of each hospital. The 2,664 subjects with 
hypertriglyceridemia and 5,294 controls had serum triglyceride 
concentrations of ≥1.69 mmol/l (150 mg/dl) and <1.69 mmol/l, 
respectively. The 974 subjects with hypo-HdL-cholesterolemia 
and 7,085 controls had serum HdL-cholesterol concentrations 
of <1.03 mmol/l (40 mg/dl) and ≥1.03 mmol/l, respectively. 
The 2,911 subjects with hyper-LdL-cholesterolemia and 
5,111 controls had serum LdL-cholesterol concentrations 
of ≥3.62 mmol/l (140 mg/dl) and <3.62 mmol/l, respec-
tively. The 562 subjects with both hypertriglyceridemia and 
hypo-HdL-cholesterolemia, and the 4,907 controls, overlapped 
between the corresponding studies, as did the 1,312 subjects 
with both hypertriglyceridemia and hyper-LdL-cholesterol-
emia and 3,723 controls, as well as the 317 subjects with both 
hypo-HdL-cholesterolemia and hyper-LdL-cholesterolemia 
and 4,484 controls. Individuals with single-gene disorders, 
such as familial hypercholesterolemia, or with endocrinologic 
or metabolic diseases that cause dyslipidemia were excluded 
from the study. Those taking medications that may cause 
secondary dyslipidemia were also excluded.
EWAS. Venous blood was collected into tubes containing 
50 mmol/l EdTA (disodium salt), peripheral blood leukocytes 
were isolated, and genomic dNA was extracted from these 
cells with the use of a kit (Genomix, Talent Srl, Trieste, Italy; 
or SMITEST EX-R&d, Medical & Biological Laboratories, 
co., Ltd., Nagoya, Japan). EWASs for hypertriglyceridemia 
(2,664 cases and 5,294 controls), hypo‑HDL‑cholesterolemia 
(974 cases and 7,085 controls), and hyper-LdL-cholesterol-
emia (2,911 cases and 5,111 controls) were performed with 
Human Exome‑12 v1.2 DNA Analysis BeadChip or Infinium 
Exome-24 v1.0 Beadchip arrays (Illumina, San diego, 
cA, USA). These exome arrays include putative functional 
exonic variants selected from ~12,000 individual exome 
and whole-genome sequences. The exonic content consists 
of ~244,000 SNPs from diverse populations, including 
European, African, chinese, and Hispanic individuals (30). 
SNPs contained in only one of the arrays (~2.6% of all SNPs) 
were excluded from analysis. Quality control was performed, 
as previously described (31). Briefly, genotyping data with a 
call rate of <97% were discarded, with the mean call rate for 
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the remaining data being 99.9%. Gender specification was 
checked for all samples, and those for which gender phenotype 
in the clinical records was inconsistent with genetic sex were 
discarded. duplicated samples and cryptic relatedness were 
checked by calculation of identity by descent; all pairs with a 
value of >0.1875 were inspected and one sample from each pair 
was excluded. Heterozygosity of SNPs was calculated for all 
samples, and those with extremely low or high heterozygosity 
(>3 standard deviations from the mean) were discarded. SNPs 
in sex chromosomes or mitochondrial dNA were excluded 
from analysis, as were non-polymorphic SNPs or SNPs with a 
minor allele frequency of <1.0%. SNPs whose genotype distri-
butions deviated significantly (P<0.01) from Hardy‑Weinberg 
equilibrium in control individuals were discarded. Finally, 
genotype data for each EWAS were examined for population 
stratification by principal components analysis (32), and popu-
lation outliers were excluded from further study. A total of 
31,198, 31,133, and 31,175 SNPs passed quality control in the 
EWASs for hypertriglyceridemia, hypo-HdL-cholesterolemia 
and hyper-LdL-cholesterolemia, respectively, and were 
subjected to further analyses.
Statistical analysis. For analysis of characteristics of the study 
subjects, quantitative and categorical data were compared 
between cases and controls with the unpaired Student's t-test 
and Pearson's chi-square test, respectively. Allele frequencies 
were estimated by the gene counting method, and depar-
ture from Hardy‑Weinberg equilibrium was identified with 
Fisher's exact test. The association of allele frequencies of 
SNPs to hypertriglyceridemia, hypo-HdL-cholesterolemia 
or hyper-LdL-cholesterolemia in the EWASs was exam-
ined with Fisher's exact test. To compensate for multiple 
comparisons of allele frequencies with hypertriglyceridemia, 
hypo-HdL-cholesterolemia, or hyper-LdL-cholesterolemia, 
Bonferroni's correction was applied for statistical significance 
of association. Given that 31,198, 31,133 or 31,175 SNPs were 
analyzed, a P‑value of <1.60x10‑6 [0.05/(31,198 or 31,175)] for 
hypertriglyceridemia and hyper-LdL-cholesterolemia and a 
P‑value of <1.61x10‑6 (0.05/31,133) for hypo-HdL-choles-
terolemia was considered statistically significant for 
association. The inflation factor (λ) was 1.07 for hypertri-
glyceridemia, 1.05 for hypo-HdL-cholesterolemia, and 
1.00 for hyper-LdL-cholesterolemia. Multivariable logistic 
regression analysis was performed with hypertriglyceridemia, 
hypo-HdL-cholesterolemia, or hyper-LdL-cholesterolemia as 
a dependent variable and independent variables including age, 
sex (0, woman; 1, man), and genotype of each SNP. Genotypes 
of SNPs were assessed according to dominant [0, AA; 1, AB + 
BB (A, major allele; B, minor allele)], recessive (0, AA + AB; 
1, BB), and additive genetic models, and the P-value, odds 
ratio, and 95% confidence interval were calculated. Additive 
models comprised additive 1 (0, AA; 1, AB; 0, BB) and addi-
tive 2 (0, AA; 0, AB; 1, BB) scenarios, which were analyzed 
simultaneously with a single statistical model. Associations 
Table I. characteristics of subjects with hypertriglyceridemia and control individuals.
characteristic control Hypertriglyceridemia P-value
Number of subjects 5,294 2,664
Age (years)   51.3±10.2 53.3±8.8 <0.0001
Sex (men/women, %) 50.2/49.8 75.6/24.4 <0.0001
Smoking (%) 35.9 54.0 <0.0001
Obesity (%) 22.9 42.6 <0.0001
Body mass index (kg/m2) 22.7±3.4 24.8±3.6 <0.0001
Hypertension (%) 35.3 57.2 <0.0001
Systolic BP (mmHg) 125±23 132±23 <0.0001
Diastolic BP (mmHg) 75±14   80±13 <0.0001
Diabetes mellitus (%) 17.5 33.8 <0.0001
Fasting plasma glucose (mmol/l)   5.83±2.04   6.55±2.81 <0.0001
Blood hemoglobin A1c (%)   5.83±1.08   6.26±1.50 <0.0001
Serum triglycerides (mmol/l)   0.94±0.34   2.40±1.37 <0.0001
Serum HDL‑cholesterol (mmol/l)   1.66±0.47   1.30±0.36 <0.0001
Serum LDL‑cholesterol (mmol/l)   3.06±0.80   3.35±0.95   0.8593
Chronic kidney disease (%) 12.3 19.9 <0.0001
Serum creatinine (µmol/l)   71.9±69.8   82.1±85.2 <0.0001
eGFR (ml min-1 1.73 m-2)   78.5±19.4   74.1±21.6 <0.0001
Hyperuricemia (%) 11.7 28.4 <0.0001
Serum uric acid (µmol/l) 308±90 362±91 <0.0001
Quantitative data are presented as mean ± standard deviation and were compared between subjects with hypertriglyceridemia and controls with 
the unpaired Student's t-test. categorical data were compared between the two groups with Pearson's chi-square test. Based on Bonferroni's 
correction, P<0.0026 (0.05/19) was considered statistically significant. BP, blood pressure; HDL, high density lipoprotein; LDL, low density 
lipoprotein; eGFR, estimated glomerular filtration rate.
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of genotypes of identified SNPs to serum concentrations of 
triglycerides, HdL-cholesterol, or LdL-cholesterol were 
examined by one-way analysis of variance. Bonferroni's 
correction was also applied to other statistical analysis as indi-
cated. Statistical tests were performed with JMP Genomics 
version 9.0 software (SAS Institute, cary, Nc, USA).
Results
Characteristics of subjects. The characteristics of the 7,958 
subjects enrolled in the hypertriglyceridemia study are listed 
in Table I. Age, the frequency of men, and the prevalence of 
smoking, obesity, hypertension, diabetes mellitus, chronic 
kidney disease, and hyperuricemia as well as body mass 
index (BMI), systolic and diastolic blood pressure (BP), 
fasting plasma glucose (FPG) level, blood glycosylated hemo-
globin (hemoglobin A1c) content, and serum concentrations 
of creatinine and uric acid were greater, whereas the serum 
concentration of HdL-cholesterol and estimated glomerular 
filtration rate (eGFR) were lower, in subjects with hypertri-
glyceridemia compared with controls.
The characteristics of the 8,059 subjects enrolled in the 
hypo-HdL-cholesterolemia study are listed in Table II. Age, 
the frequency of men, and the prevalence of smoking, obesity, 
hypertension, diabetes mellitus, chronic kidney disease, and 
hyperuricemia as well as BMI, systolic and diastolic BP, FPG 
level, blood hemoglobin A1c content, and serum concentrations 
of triglycerides, creatinine, and uric acid were greater, whereas 
eGFR was lower, in subjects with hypo-HdL-cholesterolemia 
compared with controls.
The characteristics of the 8,022 subjects enrolled in the 
hyper-LdL-cholesterolemia study are listed in Table III. Age, 
the prevalence of obesity, BMI, diastolic BP, and serum concen-
trations of triglycerides and uric acid were greater, whereas 
systolic BP and serum concentrations of HdL-cholesterol and 
creatinine were lower, in subjects with hyper-LdL-cholester-
olemia compared with controls.
EWASs for hypertriglyceridemia, hypo‑HDL‑cholesterolemia, 
and hyper‑LDL‑cholesterolemia. The association of allele 
frequencies for 31,198 SNPs that passed quality control to hyper-
triglyceridemia was examined with the use of Fisher's exact test. 
Following Bonferroni's correction, 25 SNPs were significantly 
associated with hypertriglyceridemia (P<1.60x10‑6; Table IV). 
Similar analysis of the association of allele frequencies for 
31,133 SNPs to hypo-HdL-cholesterolemia or of those for 31,175 
SNPs to hyper-LdL-cholesterolemia revealed that 28 SNPs 
were significantly associated with hypo‑HDL‑cholesterolemia 
(P<1.61x10‑6; Table V) and 65 SNPs with hyper‑LDL‑cholester-
olemia (P<1.60x10‑6; Table VI).
Multivariable logistic regression analysis of the association 
of SNPs to hypertriglyceridemia, hypo‑HDL‑cholesterol‑
emia or hyper‑LDL‑cholesterolemia. The association of the 
Table II. characteristics of subjects with hypo-HdL-cholesterolemia and control individuals.
characteristic control Hypo-HdL-cholesterolemia P-value
Number of subjects 7,085 974 
Age (years) 51.7±9.9 54.3±8.7 <0.0001
Sex (men/women, %) 55.1/44.9 85.3/14.7 <0.0001
Smoking (%) 40.5 54.6 <0.0001
Obesity (%) 27.0 48.2 <0.0001
Body mass index (kg/m2) 23.2±3.5 25.1±3.9 <0.0001
Hypertension (%) 39.6 64.8 <0.0001
Systolic BP (mmHg) 126±23 137±27 <0.0001
Diastolic BP (mmHg) 76±14 80±16 <0.0001
Diabetes mellitus (%) 19.5 48.2 <0.0001
Fasting plasma glucose (mmol/l)   5.93±2.16   7.16±3.26 <0.0001
Blood hemoglobin A1c (%)   5.89±1.17   6.59±1.60 <0.0001
Serum triglycerides (mmol/l)   1.35±0.96   2.12±1.62 <0.0001
Serum HDL‑cholesterol (mmol/l)   1.63±0.42   0.88±0.12 <0.0001
Serum LDL‑cholesterol (mmol/l)   3.16±0.84   3.13±0.99   0.2860
Chronic kidney disease (%) 13.4 26.2 <0.0001
Serum creatinine (µmol/l)   72.6±66.6    96.0±122.7 <0.0001
eGFR (ml min-1 1.73 m-2)   77.5±18.5   73.3±29.8 <0.0001
Hyperuricemia (%) 15.9 27.2 <0.0001
Serum uric acid (µmol/l) 323±91 361±0.3 <0.0001
Quantitative data are presented as mean ± standard deviation and were compared between subjects with hypo-HdL-cholesterolemia and 
controls with the unpaired Student's t-test. categorical data were compared between the two groups with Pearson's chi-square test. Based on 
Bonferroni's correction, P<0.0026 (0.05/19) was considered statistically significant. BP, blood pressure; HDL, high density lipoprotein; LDL, 
low density lipoprotein; eGFR, estimated glomerular filtration rate.
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25 SNPs identified in the EWAS for hypertriglyceridemia 
to this condition was further examined by multivariable 
logistic regression analysis, following adjustment for age and 
sex. All 25 SNPs were significantly [P<0.0005 (0.05/100) 
in at least one genetic model] associated with hypertriglyc-
eridemia (Table VII). Similar analysis revealed that all 28 
SNPs identified in the EWAS for hypo‑HDL‑cholesterolemia 
[P<0.0004 (0.05/112); Table VIII] and all 65 SNPs identi-
fied in the EWAS for hyper‑LDL‑cholesterolemia [P<0.0002 
(0.05/260); Table IX] were significantly associated with the 
respective conditions.
Association of identified SNPs to serum concentrations 
of triglycerides, HDL‑cholesterol or LDL‑cholesterol. 
The association of the genotypes of identified SNPs to 
serum concentrations of triglycerides, HdL-cholesterol, 
or LdL-cholesterol was examined by one-way analysis 
of variance. The 25 SNPs identified in the EWAS for 
hypertriglyceridemia were all significantly associated with 
serum triglyceride concentration [P<0.0020 (0.05/25); 
Table X]. Among the 28 SNPs identified in the EWAS 
for hypo-HdL-cholesterolemia, 27 polymorphisms were 
significantly associated with the serum HDL‑cholesterol level 
[P<0.0018 (0.05/28)], whereas rs114501427 of SPOPL was not 
related to this parameter (Table XI). Among the 65 SNPs iden-
tified in the EWAS for hyper‑LDL‑cholesterolemia, 37 SNPs 
were significantly associated with serum LDL‑cholesterol 
concentration [P<0.0008 (0.05/65); Table XII]. It is possible 
that the lack of significant correlation between the remaining 
28 SNPs and the serum LdL-cholesterol levels may be due to 
effects of medical treatment.
Linkage disequilibrium analysis. The linkage disequi-
librium (Ld) was assessed among SNPs associated with 
hypertriglyceridemia, hypo-HdL-cholesterolemia, or 
hyper-LdL-cholesterolemia. For the hypertriglyceridemia 
study, strong LD was apparent among rs1260326 and rs780093 
of GCKR and rs1260333 at chromosome 2p23 [square of the 
correlation coefficient (r2), 0.876‑0.983]. An LD plot for the 12 
SNPs located at chromosomal region 8p21.3 is illustrated in 
Fig. 1. Strong LD was observed among rs301, rs326, rs13702, 
and rs15285 of LPL, rs2083637 and rs1441756 (r2, 0.942-0.988), 
as well as among rs328 of LPL, rs10096633, rs17482753, 
rs12678919, rs10503669 and rs7016880 (r2, 0.910-0.999). An 
Ld plot for the eight SNPs located at chromosomal region 
11q23.3 is illustrated in Fig. 2. Significant LD was apparent 
among rs10790162 of BUD13, rs7350481, rs9326246, both 
rs964184 and rs2075290 of ZPR1, and rs2266788 of APOA5 
(r2, 0.687‑0.990).
For the hypo-HdL-cholesterolemia study, significant 
Ld was apparent between rs139537100 of MOB3C and 
rs115287176 of TMOD4 (r2, 0.984); between rs116417209 
of EHD3 and rs114501427 of SPOPL (r2, 0.703); between 
rs140232911 of ZNF860 and rs35874056 of CACNA1D 
Table III. characteristics of subjects with hyper-LdL-cholesterolemia and control individuals.
characteristic control Hyper-LdL-cholesterolemia P-value
Number of subjects 5,111 2,911 
Age (years)   51.3±10.3 53.2±8.9 <0.0001
Sex (men/women, %) 59.0/41.0 58.2/41.8   0.4936
Smoking (%) 40.9 44.3   0.0034
Obesity (%) 27.7 32.6 <0.0001
Body mass index (kg/m2) 23.2±3.6 23.9±3.5 <0.0001
Hypertension (%) 42.5 42.6   0.8966
Systolic BP (mmHg) 128±25 126±21   0.0025
Diastolic BP (mmHg)   76±14   77±13   0.0004
diabetes mellitus (%) 23.2 22.0   0.2593
Fasting plasma glucose (mmol/l)   6.11±2.49   6.02±2.12   0.0831
Blood hemoglobin A1c (%)   5.96±1.25   5.99±1.26   0.4573
Serum triglycerides (mmol/l)   1.40±1.19   1.52±0.91 <0.0001
Serum HDL‑cholesterol (mmol/l)   1.56±0.49   1.51±0.42 <0.0001
Serum LDL‑cholesterol (mmol/l)   2.70±0.56   3.90±0.74 <0.0001
chronic kidney disease (%) 15.3 14.3    0.2118
Serum creatinine (µmol/l)   78.3±88.7   71.7±58.9   0.0001
eGFR (ml min-1 1.73 m-2)   77.0±21.7   76.8±17.8   0.7007
Hyperuricemia (%) 16.3 18.9   0.0028
Serum uric acid (µmol/l) 323±97 334±87 <0.0001
Quantitative data are presented as mean ± standard deviation and were compared between subjects with hyper-LdL-cholesterolemia and 
controls with the unpaired Student's t-test. categorical data were compared between the two groups with Pearson's chi-square test. Based on 
Bonferroni's correction, P<0.0026 (0.05/19) was considered statistically significant. BP, blood pressure; HDL, high density lipoprotein; LDL, 
low density lipoprotein; eGFR, estimated glomerular filtration rate.
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(r2, 1.00); among rs192210727 of ADGRL3, rs188378669 of 
CXCL8, and rs61734696 of MARCH1 (r2, 0.901 to 0.972); 
between rs199921354 of VPS33B and rs141569282 of OR4F6 
(r2, 0.994); and between rs247616 and rs3764261 at chromo-
some 16q13 (r2, 0.992). An LD plot for the five SNPs located 
at chromosomal region 12q24.12 to 12q24.13 is illustrated in 
Fig. 3. Significant LD was detected among rs3782886 of BRAP, 
rs11066015 of ACAD10, rs671 of ALDH2, and rs2074356 and 
rs11066280 of HECTD4 (r2, 0.813-0.995).
For the hyper‑LDL‑cholesterolemia study, significant LD 
was apparent among rs147284320 of PTCH2, rs139537100 
of MOB3C and rs115287176 of TMOD4 (r2, 0.828-0.984); 
among rs192210727 of ADGRL3, rs188378669 of CXCL8, 
and rs61734696 of MARCH1 (r2, 0.901-0.972); and between 
rs200787930 of PLCB2 and rs199921354 of VPS33B (r2, 
0.994). An Ld plot for the 47 SNPs located at chromosomal 
region 6p22.3 to 6p21.3 is illustrated in Fig. 4. There were 
two major LD blocks. The first LD block (r2, 0.571-1.000) 
comprised rs7749235, rs2285321, and rs6937357 of DHX16; 
rs9468805, rs6457254, and rs2394392 of PPP1R18; rs3130663 
at 6p21.3; rs2269702, rs28986465, rs2075015, and rs6924270 
of MDC1; and rs3132584, rs25527, and rs9500864 of 
TUBB. The second Ld block (r2, 0.762‑1.000) comprised 
rs147733073 of CCHCR1; rs2596574 at 6p21.3; rs11538264 
of PRRC2A; rs9267546, rs17200983, and rs9267547 of 
LY6G6F; rs117894946 of LY6G6C; rs11754464 of MSH5; 
rs5030798 and rs11751198 of VARS; rs6457452 of HSPA1B; 
rs11968400 of C6orf48; rs12210887 at 6p21.3; rs13118 of 
NEU1; rs117127493 of SLC44A4; rs492899 of SKIV2L; 
rs140770834 and rs11751545 of TNXB; and rs204999 at 
6p21.3. Significant LD was also observed between rs4576240 
of KIAA0319 and rs150142878 of FAM65B (r2, 0.893); among 
rs34902660 of SLC17A3, rs76463649 of ZSCAN26, rs6922302 
of ZSCAN31, rs29243 of GABBR1, and rs2523995 of TRIM40 
(r2, 0.601‑0.995); between rs64036 of UBD and rs2524272 at 
6p22.1 (r2, 0.753); and among rs6933400 and rs11970154 of 
DPCR1, rs2508015 at 6p21.3, and rs147733073 of CCHCR1 
(r2, 0.596‑0.987).
Relation of SNPs identif ied in the present study to 
dyslipidemia‑related phenotypes examined in previous 
GWASs. The relation of genes, chromosomal loci and SNPs 
identified in the present study was further analyzed against 
phenotypes previously examined by GWASs available in the 
Table IV. The 25 SNPs significantly associated with hypertriglyceridemia in the exome‑wide association study.
  Nucleotide Amino acid     Allele
Gene SNP substitutiona substitution chromosome Position MAF (%) Allele OR frequency (P-value)
APOA5 rs2075291 G/T G185C 11 116790676 7.3 1.89 2.83x10-24
BUD13 rs10790162 G/A  11 116639104 26.3 1.47 3.58x10-24
ZPR1 rs964184 C/G  11 116778201 26.3 1.46 8.82x10-24
APOA5 rs2266788 T/C  11 116789970 26.2 1.47 1.27x10-23
 rs7350481 C/T  11 116715567 27.7 1.44 7.94x10-23
 rs9326246 G/C  11 116741017 26.5 1.45 1.36x10-22
ZPR1 rs2075290 T/C  11 116782580 26.7 1.43 1.58x10-21
 rs12678919 A/G  8 19986711 12.6 0.71 6.07x10-11
 rs10503669 C/A  8 19990179 12.6 0.71 8.32x10-11
 rs17482753 G/T  8 19975135 12.6 0.72 2.04x10-10
 rs10096633 C/T  8 19973410 12.7 0.72 2.50x10-10
LPL rs328 C/G S474* 8 19962213 12.9 0.72 2.72x10-10
APOA4 rs5104 A/G N147S 11 116821618 35.7 1.25 2.78x10-10
 rs7016880 G/C  8 20019235 12.0 0.72 1.72x10-9
GCKR rs1260326 T/C L446P 2 27508073 43.6 0.82 6.27x10-9
GCKR rs780093 A/G  2 27519736 43.0 0.83 2.18x10-8
 rs1260333 T/C  2 27525757 42.9 0.83 4.38x10-8
 rs11085421 A/c  19 20985948 19.1 0.79 1.59x10-7
 rs1441756 T/G  8 20010875 19.0 0.80 5.61x10-7
 rs2083637 T/C  8 20007664 19.0 0.81 6.24x10-7
LPL rs301 T/c  8 19959423 19.3 0.81 7.70x10-7
LPL rs13702 A/G  8 19966981 19.2 0.81 9.15x10-7
LPL rs15285 G/A  8 19967156 19.2 0.81 1.02x10‑6
 rs2954033 G/A  8 125481504 33.3 1.19 1.02x10‑6
LPL rs326 A/G  8 19961928 19.4 0.81 1.24x10‑6
Allele frequencies were analyzed with Fisher's exact test. P<1.60x10‑6 was considered statistically significant. aMajor allele/minor allele. SNP, 
single nucleotide polymorphism; MAF, minor allele frequency; OR, odds ratio.
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Genome-Wide Repository of Associations Between SNPs 
and Phenotypes (GRASP) Search v.2.0.0.0 (https://grasp.
nhlbi.nih.gov/Search.aspx) developed by the Information 
Technology and Applications center, National center for 
Biotechnology Information, National Heart, Lung, and 
Blood Institute, National Institutes of Health (Bethesda, Md, 
USA) (33,34).
In the hypertriglyceridemia study, GCKR, chromosomal 
region 2p23, LPL, region 8p21.3, region 8q24.2, BUD13, 
region 11q23.3, ZPR1, APOA5, and APOA4 have been previ-
ously reported to be associated with circulating triglyceride 
concentrations, whereas chromosome 19p12 had not been 
related to triglyceride levels or other dyslipidemia-related 
traits (Table XIII).
In the study of hypo-HdL-cholesterolemia, APOA5, 
BRAP, ALDH2, HECTD4, chromosome 16q13, CETP, and 
LILRB2 were previously reported to be associated with circu-
lating HdL-cholesterol levels, whereas CXCL8, ACAD10, 
and PLCB2 were associated with circulating levels of total 
cholesterol, LdL-cholesterol, and triglycerides, respectively 
(Table XIV). MARCH1, chromosome 6p22.1, and VPS33B 
were also associated with adiponectin concentrations, type 1 
diabetes mellitus, and type 2 diabetes mellitus, respectively. 
The remaining 13 genes (MOB3C, TMOD4, LPGAT1, EHD3, 
SPOPL, COL6A3, ZNF860, CACNA1D, COL6A5, ADGRL3, 
DCLRE1C, OR4F6, ZNF77) had not been related to circulating 
HdL-cholesterol or other dyslipidemia-related phenotypes.
In the study of hyper-LdL-cholesterolemia, PCSK9, APOB, 
chromosome 6p21.3, SKIV2L, HECTD4, APOE, and APOC1 
were previously reported to be associated with circulating 
LdL-cholesterol levels, whereas CXCL8, 6p21.3, CCHCR1, 
PRRC2A, LY6G6F, MSH5, C6orf48, SLC44A4, TNXB, and 
PLCB2 were associated with circulating concentrations of total 
cholesterol or triglycerides (Table XV). MARCH1, SLC17A3, 
ZSCAN31, GABBR1, 6p22.1, TRIM40, PPP1R18, 6p21.3, 
MDC1, TUBB, DPCR1, LY6G6C, VARS, HSPA1B, and VPS33B 
Table V. The 28 SNPs significantly associated with hypo-HdL-cholesterolemia in the exome-wide association study.
        Allele
  Nucleotide Amino acid     frequency
Gene SNP substitutiona substitution chromosome Position MAF (%) Allele OR  (P-value)
LPGAT1 rs150552771 T/C K200E 1 211783358 5.0 16.67 1.09x10-12
APOA5 rs2075291 G/T G185C 11 116790676 7.3 1.79 4.10x10-12
COL6A5 rs200982668 G/A E2501K 3 130470894 1.3 0.18 4.51x10-11
ZNF860 rs140232911 C/T S161L 3 31989561 10.4 4.39 5.21x10-11
 rs9261800 C/G  6 30408822 2.8 19.65 6.69x10-11
VPS33B rs199921354 c/T R80Q 15 91013841 1.2 0.17 1.03x10-10
ADGRL3 rs192210727 G/T R580I 4 61909615 1.3 0.19 1.33x10-10
TMOD4 rs115287176 G/A R277W 1 151170961 1.2 0.18 1.46x10-10
COL6A3 rs146092501 C/T E1386K 2 237371861 1.2 0.18 2.10x10-10
MARCH1 rs61734696 G/T Q137K 4 164197303 1.2 0.19 2.74x10-10
PLCB2 rs200787930 C/T E1106K 15 40289298 1.2 0.19 2.79x10-10
MOB3C rs139537100 C/T R24Q 1 46615006 1.2 0.19 2.87x10-10
CXCL8 rs188378669 G/T E31* 4 73741568 1.2 0.19 3.94x10-10
EHD3 rs116417209 G/A V151I 2 31249417 3.5 12.5 5.66x10-10
ZNF77 rs146879198 G/A R340* 19 2934109 1.2 0.20 1.17x10-9
OR4F6 rs141569282 G/A A117T 15 101806068 1.7 0.23 2.31x10-9
ACAD10 rs11066015 G/A  12 111730205 27.5 1.37 2.61x10-9
CACNA1D rs35874056 G/A G460S 3 53702798 2.0 100.00 2.95x10-9
ALDH2 rs671 G/A E504K 12 111803962 27.6 1.35 4.23x10-9
 rs3764261 G/T  16 56959412 19.8 0.69 7.90x10-9
 rs247616 C/T  16 56955678 19.7 0.69 9.31x10-9
BRAP rs3782886 A/G  12 111672685 29.3 1.34 1.19x10-8
CETP rs1532624 G/T  16 56971567 29.6 0.74 2.63x10-8
HECTD4 rs11066280 T/A  12 112379979 29.0 1.33 3.54x10-8
HECTD4 rs2074356 C/T  12 112207597 25.4 1.32 1.43×10-7
LILRB2 rs73055442 C/T R103H 19 54279838 1.6 34.09 1.80x10-7
DCLRE1C rs150854849 C/T R179Q 10 14934704 2.4 59.56 3.16x10-7
SPOPL rs114501427 G/A D349N 2 138568946 8.8 3.23 4.01x10-7
Allele frequencies were analyzed with Fisher's exact test. P<1.61x10‑6 was considered statistically significant. aMajor allele/minor allele. SNP, 
single nucleotide polymorphism; MAF, minor allele frequency; OR, odds ratio.
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Table VI. The 65 SNPs significantly associated with hyper-LdL-cholesterolemia in the exome-wide association study.
        Allele
  Nucleotide Amino acid     frequency
Gene SNP substitutiona substitution chromosome Position MAF (%) Allele OR  (P-value)
APOE rs7412 C/T R176C 19 44908822 4.3 0.42 6.62x10-22
COL6A3 rs146092501 C/T E1386K 2 237371861 1.2 2.14 1.42x10-11
TMOD4 rs115287176 G/A R277W 1 151170961 1.2 2.13 1.83x10-11
CXCL8 rs188378669 G/T E31* 4 73741568 1.2 2.10 1.95x10-11
VPS33B rs199921354 c/T R80Q 15 91013841 1.2 2.11 2.32x10-11
ZNF77 rs146879198 G/A R340* 19 2934109 1.2 2.08 4.91x10-11
MOB3C rs139537100 C/T R24Q 1 46615006 1.2 2.06 5.58x10-11
PLCB2 rs200787930 C/T E1106K 15 40289298 1.2 2.03 1.70x10-10
MUC17 rs78010183 A/T T1305S 7 101035329 1.8 1.81 2.30x10-10
MARCH1 rs61734696 G/T Q137K 4 164197303 1.2 2.01 3.49x10-10
APOB rs13306206 G/A P955S 2 21019859 3.2 1.75 7.32x10-10
COL6A5 rs200982668 G/A E2501K 3 130470894 1.3 1.92 9.85x10-10
PTCH2 rs147284320 C/T V503I 1 44828589 2.0 1.86 1.23x10-9
ADGRL3 rs192210727 G/T R580I 4 61909615 1.3 1.94 1.49x10-9
APOC1 rs445925 C/T  19 44912383 6.6 0.66 3.62x10-9
HSPA1B rs6457452 C/T  6 31827773 9.7 1.33 2.97x10-8
C6orf48 rs11968400 C/T  6 31836952 9.7 1.33 3.96x10-8
 rs12210887 G/T  6 31847946 9.7 1.33 5.26x10-8
UBD rs64036 C/A  6 29559490 22.5 1.23 7.55x10-8
CCHCR1 rs147733073 C/G H539Q 6 31145462 10.2 1.32 8.01x10-8
VARS rs11751198 G/A  6 31785749 9.5 1.33 8.12x10-8
 rs2596574 G/A  6 31366397 9.7 1.32 8.83x10-8
LY6G6F rs9267547 G/A A107T 6 31707724 10.0 1.32 9.72x10-8
NEU1 rs13118 T/A  6 31859509 9.7 1.32 1.01x10-7
SLC17A3 rs34902660 C/A G239V 6 25850874 8.4 1.35 1.04x10-7
FAM65B rs150142878 C/T R371Q 6 24847657 5.6 1.42 1.18x10-7
TUBB rs9500864 G/A  6 30725455 20.4 1.23 1.19x10-7
 rs204999 A/G  6 32142202 9.1 1.33 1.34x10-7
 rs3130663 A/G  6 30698817 10.7 1.28 1.38x10-7
VARS rs5030798 G/A V1055I 6 31779733 9.5 1.32 1.43x10-7
LY6G6F rs9267546 G/A  6 31705659 9.8 1.32 1.44x10-7
PRRC2A rs11538264 G/A V1774M 6 31635412 9.5 1.32 1.55x10-7
DPCR1 rs11970154 G/C G1213R 6 30952101 13.3 1.28 1.60x10-7
MSH5 rs11754464 C/T  6 31755958 9.5 1.32 1.73x10-7
PCSK9 rs151193009 c/T R93c 1 55043912 1.1 0.42 1.85x10-7
GABBR1 rs29243 C/T  6 29631325 10.6 1.30 1.94x10-7
KIAA0319 rs4576240 G/T P133T 6 24596250 5.5 1.41 2.10x10-7
LY6G6F rs17200983 C/A P34Q 6 31707506 9.5 1.32 2.38x10-7
TNXB rs140770834 C/G L2271V 6 32064851 8.8 1.32 2.42x10-7
TNXB rs11751545 A/C  6 32073266 8.8 1.32 2.42x10-7
DPCR1 rs6933400 C/T  6 30939399 13.2 1.27 2.43x10-7
LY6G6C rs117894946 G/C G75A 6 31719250 9.5 1.32 2.66x10-7
SLC44A4 rs117127493 G/C E344Q 6 31869232 8.9 1.32 3.22x10-7
ZSCAN26 rs76463649 A/G N15S 6 28271963 9.6 1.30 4.26x10-7
DHX16 rs7749235 T/C  6 30667816 17.8 1.23 4.67x10-7
LOC105‑ rs9264942 T/C  6 31306603 40.1 1.18 4.82x10-7
375015
ZSCAN31 rs6922302 C/G P128A 6 28327533 9.6 1.30 5.06x10-7
MDC1 rs2269702 A/G  6 30707358 17.7 1.23 5.13x10-7
MDC1 rs28986465 C/T P386L 6 30712785 17.7 1.23 5.17x10-7
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Table VI. continued.
        Allele
  Nucleotide Amino acid     frequency
Gene SNP substitutiona substitution chromosome Position MAF (%) Allele OR  (P-value)
MDC1 rs2075015 G/A E371K 6 30712831 17.7 1.23 5.17x10-7
DHX16 rs2285321 T/C  6 30670221 17.8 1.23 5.18x10-7
SKIV2L rs492899 A/G  6 31965741 9.1 1.31 5.33x10-7
MDC1 rs6924270 A/G  6 30714203 17.8 1.23 5.81x10-7
 rs2508015 C/T  6 31042423 11.7 1.27 6.07x10-7
TUBB rs25527 C/T  6 30723161 21.0 1.22 6.08x10-7
PPP1R18 rs9468805 G/A  6 30675932 17.7 1.23 7.07x10-7
DHX16 rs6937357 T/C  6 30672547 17.8 1.23 7.07x10-7
HECTD4 rs11066280 T/A  12 112379979 29.0 1.19 7.09x10-7
TRIM40 rs2523995 G/A  6 30134407 10.6 1.28 7.88x10-7
PPP1R18 rs6457254 C/T  6 30681357 17.9 1.22 1.20x10‑6
TUBB rs3132584 C/A  6 30720650 21.2 1.20 1.22x10‑6
 rs3130685 T/C  6 31238429 41.6 0.85 1.43x10‑6
GIT2 rs2292354 C/T  12 109930396 26.2 0.83 1.45x10‑6
PPP1R18 rs2394392 T/G  6 30682541 18.0 1.22 1.50x10‑6
 rs2524272 T/C  6 29714623 26.8 1.19 1.55x10‑6
Allele frequencies were analyzed with Fisher's exact test. P<1.60x10‑6 was considered statistically significant. aMajor allele/minor allele. SNP, 
single nucleotide polymorphism; MAF, minor allele frequency; OR, odds ratio.
Figure 2. Ld map for eight SNPs at chromosomal region 11q23.3 associated with hypertriglyceridemia. Ld was calculated as the square of the correlation coef-
ficient (r2), with the extent of Ld increasing according to the color order of blue to gray to red. Ld, linkage disequilibrium; SNP, single nucleotide polymorphism.
Figure 1. Ld map for 12 SNPs at chromosomal region 8p21.3 associated with hypertriglyceridemia. Ld was calculated as the square of the correlation coef-
ficient (r2), with the extent of Ld increasing according to the color order of gray to red. Ld, linkage disequilibrium; SNP, single nucleotide polymorphism.
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Table X. Association of SNPs identified in the present study to serum triglyceride concentration.
Gene SNP Serum triglycerides (mmol/l) P-value
APOA5 rs2075291 G/T GG GT TT <0.0001
   1.39±0.98 1.83±1.55 2.56±2.27 
BUD13 rs10790162 G/A GG GA AA <0.0001
   1.35±1.00 1.54±1.18 1.77±1.31 
ZPR1 rs964184 C/G CC CG GG <0.0001
   1.35±1.00 1.55±1.18 1.75±1.30 
APOA5 rs2266788 T/C TT TC CC <0.0001
   1.35±1.00 1.54±1.17 1.76±1.30 
 rs7350481 C/T CC CT TT <0.0001
   1.34±0.95 1.56±1.24 1.68±1.19 
 rs9326246 G/C GG GC CC <0.0001
   1.35±1.00 1.54±1.18 1.74±1.28 
ZPR1 rs2075290 T/C TT TC CC <0.0001
   1.36±1.01 1.54±1.17 1.74±1.29 
 rs12678919 A/G AA AG GG <0.0001
   1.49±1.11 1.33±1.03 1.32±1.37 
 rs10503669 C/A CC CA AA <0.0001
   1.49±1.11 1.33±1.03 1.32±1.38 
 rs17482753 G/T GG GT TT <0.0001
   1.49±1.11 1.33±1.02 1.31±1.35 
 rs10096633 C/T CC CT TT <0.0001
   1.49±1.11 1.33±1.03 1.31±1.34 
LPL rs328 C/G CC CG GG <0.0001
   1.49±1.11 1.33±1.02 1.33±1.33 
APOA4 rs5104 A/G AA AG GG <0.0001
   1.37±1.00 1.49±1.12 1.57±1.28 
 rs7016880 G/C GG GC CC <0.0001
   1.49±1.11 1.33±1.04 1.30±1.35 
GCKR rs1260326 T/C TT TC CC <0.0001
   1.54±1.14 1.44±1.14 1.33±0.89 
GCKR rs780093 A/G AA AG GG <0.0001
   1.53±1.12 1.45±1.16 1.33±0.87 
 rs1260333 T/C TT TC CC <0.0001
   1.53±1.12 1.45±1.16 1.32±0.87 
 rs11085421 A/C AA AC CC <0.0001
   1.49±1.14 1.39±1.05 1.27±0.70 
 rs1441756 T/G TT TG GG <0.0001
   1.49±1.12 1.38±1.04 1.34±1.16 
 rs2083637 T/C TT TC CC <0.0001
   1.49±1.12 1.38±1.05 1.34±1.16 
LPL rs301 T/C TT TC CC <0.0001
   1.49±1.11 1.38±1.08 1.34±1.14 
LPL rs13702 A/G AA AG GG <0.0001
   1.50±1.12 1.38±1.04 1.34±1.15 
LPL rs15285 G/A GG GA AA <0.0001
   1.50±1.12 1.38±1.04 1.34±1.15 
 rs2954033 G/A GG GA AA 0.0007
   1.41±1.02 1.47±1.16 1.55±1.18 
LPL rs326 A/G AA AG GG <0.0001
   1.49±1.11 1.38±1.07 1.35±1.14 
data are presented as mean ± standard deviation and were compared among genotypes by one-way analysis of variance. Based on Bonferroni's 
correction, P<0.0020 (0.05/25) was considered statistically significant. SNP, single nucleotide polymorphism.
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Table XI. Association of SNPs identified in the present study to serum HDL‑cholesterol concentration.
Gene SNP Serum HdL-cholesterol (mmol/l) P-value
LPGAT1 rs150552771 T/C TT TC  <0.0001
   1.54±0.47 1.11±0.63  
APOA5 rs2075291 G/T GG GT TT <0.0001
   1.56±0.47 1.42±0.45 1.29±0.40 
COL6A5 rs200982668 G/A GG GA  <0.0001
   1.53±0.47 1.69±0.44  
ZNF860 rs140232911 c/T cc cT  0.0003
   1.54±0.47 1.37±0.59  
 rs9261800 C/G CC CG  <0.0001
   1.54±0.47 0.98±0.56  
VPS33B rs199921354 C/T CC CT  <0.0001
   1.53±0.47 1.69±0.44  
ADGRL3 rs192210727 G/T GG GT TT <0.0001
   1.53±0.47 1.67±0.44 1.91±0.49 
TMOD4 rs115287176 G/A GG GA  <0.0001
   1.53±0.47 1.68±0.44  
COL6A3 rs146092501 C/T CC CT  <0.0001
   1.53±0.47 1.68±0.44  
MARCH1 rs61734696 G/T GG GT  <0.0001
   1.53±0.47 1.69±0.44  
PLCB2 rs200787930 C/T CC CT  <0.0001
   1.53±0.47 1.69±0.44  
MOB3C rs139537100 C/T CC CT  <0.0001
   1.53±0.47 1.68±0.44  
CXCL8 rs188378669 G/T GG GT  <0.0001
   1.53±0.47 1.69±0.44  
EHD3 rs116417209 G/A GG GA  <0.0001
   1.54±0.47 1.09±0.48  
ZNF77 rs146879198 G/A GG GA  <0.0001
   1.53±0.47 1.69±0.44  
OR4F6 rs141569282 G/A GG GA  <0.0001
   1.48±0.46 1.72±0.43  
ACAD10 rs11066015 G/A GG GA AA <0.0001
   1.57±0.48 1.51±0.47 1.43±0.43 
CACNA1D rs35874056 G/A GG GA  <0.0001
   1.51±0.47 0.94±0.64  
ALDH2 rs671 G/A GG GA AA <0.0001
   1.57±0.48 1.51±0.47 1.43±0.43 
 rs3764261 G/T GG GT TT <0.0001
   1.50±0.46 1.59±0.48 1.72±0.49 
 rs247616 C/T CC CT TT <0.0001
   1.50±0.46 1.59±0.48 1.71±0.50 
BRAP rs3782886 A/G AA AG GG <0.0001
   1.57±0.48 1.52±0.47 1.44±0.43 
CETP rs1532624 G/T GG GT TT <0.0001
   1.50±0.46 1.56±0.47 1.64±0.48 
HECTD4 rs11066280 T/A TT TA AA <0.0001
   1.57±0.47 1.52±0.47 1.44±0.42 
HECTD4 rs2074356 C/T CC CT TT <0.0001
   1.57±0.48 1.51±0.47 1.44±0.43 
LILRB2 rs73055442 C/T CC CT  <0.0001
   1.54±0.47 0.88±0.31  
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Table XI. continued.
Gene SNP Serum HdL-cholesterol (mmol/l) P-value
DCLRE1C rs150854849 C/T CC CT  <0.0001
   1.54±0.47 0.92±0.68  
SPOPL rs114501427 G/A GG GA  0.0041
   1.54±0.47 1.41±0.58  
data are presented as mean ± standard deviation and were compared among genotypes by one-way analysis of variance. Based on Bonferroni's 
correction, P<0.0018 (0.05/28) was considered statistically significant. SNP, single nucleotide polymorphism; HDL, high density lipoprotein.
Table XII. Association of SNPs identified in the present study to serum LDL‑cholesterol concentration.
Gene SNP Serum LdL-cholesterol (mmol/l) P-value
APOE rs7412 c/T cc cT TT <0.0001
   3.20±0.85 2.74±0.80 2.39±1.48 
COL6A3 rs146092501 C/T CC CT  0.1168
   3.16±0.86 3.24±0.82  
TMOD4 rs115287176 G/A GG GA  0.1624
   3.16±0.86 3.23±0.82  
CXCL8 rs188378669 G/T GG GT  0.1158
   3.16±0.86 3.24±0.82  
VPS33B rs199921354 c/T cc cT  0.1121
   3.16±0.86 3.24±0.81  
ZNF77 rs146879198 G/A GG GA  0.2277
   3.16±0.86 3.22±0.81  
MOB3C rs139537100 c/T cc cT  0.2422
   3.16±0.86 3.21±0.82  
PLCB2 rs200787930 C/T CC CT  0.1860
   3.16±0.86 3.22±0.81  
MUC17 rs78010183 A/T AA AT  0.0096
   3.15±0.87 3.26±0.78  
MARCH1 rs61734696 G/T GG GT  0.3029
   3.16±0.86 3.21±0.80  
APOB rs13306206 G/A GG GA AA <0.0001
   3.14±0.85 3.42±0.98 4.20±0.86 
COL6A5 rs200982668 G/A GG GA  0.3549
   3.16±0.86 3.20±0.80  
PTCH2 rs147284320 c/T cc cT  0.5075
   3.17±0.82 3.20±0.82  
ADGRL3 rs192210727 G/T GG GT TT 0.6309
   3.16±0.86 3.20±0.81 2.99±0.82 
APOC1 rs445925 c/T cc cT TT <0.0001
   3.19±0.86 2.96±0.86 2.99±1.21 
HSPA1B rs6457452 C/T CC CT TT <0.0001
   3.14±0.85 3.24±0.89 3.38±0.88 
C6orf48 rs11968400 C/T CC CT TT <0.0001
   3.14±0.85 3.24±0.89 3.37±0.88 
 rs12210887 G/T GG GT TT <0.0001
   3.14±0.85 3.24±0.89 3.37±0.89 
UBD rs64036 C/A CC CA AA 0.0004
   3.13±0.85 3.19±0.87 3.27±0.85 
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Table XII. continued.
Gene SNP Serum LdL-cholesterol (mmol/l) P-value
CCHCR1 rs147733073 c/G cc cG GG <0.0001
   3.14±0.85 3.23±0.89 3.37±0.88 
VARS rs11751198 G/A GG GA AA <0.0001
   3.14±0.85 3.24±0.89 3.37±0.89 
 rs2596574 G/A GG GA AA <0.0001
   3.14±0.85 3.24±0.89 3.35±0.86 
LY6G6F rs9267547 G/A GG GA AA <0.0001
   3.14±0.85 3.23±0.89 3.37±0.89 
NEU1 rs13118 T/A TT TA AA <0.0001
   3.14±0.85 3.24±0.89 3.37±0.89 
SLC17A3 rs34902660 C/A CC CA AA <0.0001
   3.14±0.85 3.26±0.90 3.35±0.91 
FAM65B rs150142878 c/T cc cT TT <0.0001
   3.14±0.85 3.30±0.94 3.18±0.88 
TUBB rs9500864 G/A GG GA AA 0.0002
   3.13±0.85 3.19±0.87 3.28±0.90 
 rs204999 A/G AA AG GG <0.0001
   3.14±0.85 3.24±0.89 3.36±0.91 
 rs3130663 A/G AA AG GG 0.0010
   3.14±0.85 3.22±0.88 3.22±0.90 
VARS rs5030798 G/A GG GA AA <0.0001
   3.14±0.85 3.24±0.89 3.37±0.89 
LY6G6F rs9267546 G/A GG GA AA <0.0001
   3.14±0.85 3.24±0.89 3.36±0.87 
PRRC2A rs11538264 G/A GG GA AA <0.0001
   3.14±0.85 3.24±0.90 3.36±0.88 
DPCR1 rs11970154 G/c GG Gc cc <0.0001
   3.13±0.85 3.23±0.89 3.32±0.86 
MSH5 rs11754464 C/T CC CT TT <0.0001
   3.14±0.85 3.24±0.89 3.37±0.89 
PCSK9 rs151193009 c/T cc cT TT <0.0001
   3.17±0.86 2.77±0.73 2.05 
GABBR1 rs29243 c/T cc cT TT 0.0001
   3.14±0.85 3.23±0.89 3.34±0.86 
KIAA0319 rs4576240 G/T GG GT TT <0.0001
   3.14±0.85 3.30±0.93 3.17±0.89 
LY6G6F rs17200983 c/A cc cA AA <0.0001
   3.14±0.85 3.24±0.89 3.36±0.88 
TNXB rs140770834 c/G cc cG GG <0.0001
   3.14±0.85 3.24±0.89 3.37±0.92 
TNXB rs11751545 A/c AA Ac cc <0.0001
   3.14±0.85 3.24±0.89 3.37±0.92 
DPCR1 rs6933400 C/T CC CT TT <0.0001
   3.13±0.85 3.23±0.89 3.32±0.87 
LY6G6C rs117894946 G/C GG GC CC <0.0001
   3.14±0.85 3.24±0.89 3.36±0.88 
SLC44A4 rs117127493 G/c GG Gc cc <0.0001
   3.14±0.85 3.24±0.89 3.36±0.91 
ZSCAN26 rs76463649 A/G AA AG GG <0.0001
   3.14±0.85 3.24±0.89 3.37±0.85 
DHX16 rs7749235 T/c TT Tc cc 0.0010
   3.14±0.85 3.20±0.87 3.28±0.90 
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were associated with diabetes mellitus-associated phenotypes. 
The remaining 16 genes (PTCH2, MOB3C, TMOD4, COL6A3, 
COL6A5, ADGRL3, KIAA0319, FAM65B, ZSCAN26, UBD, 
DHX16, LOC105375015, NEU1, MUC17, GIT2, ZNF77) 
had not been related to circulating LdL-cholesterol or other 
dyslipidemia-related phenotypes.
Network analysis of genes identified in the present study. 
Network analysis of the 10 genes (MOB3C, TMOD4, LPGAT1, 
EHD3, COL6A3, ZNF860, CACNA1D, COL6A5, DCLRE1C, 
ZNF77) or three genes (KIAA0319, FAM65B, UBD) associ-
ated in the present study with hypo-HdL-cholesterolemia 
or hyper-LdL-cholesterolemia, respectively, was performed 
Table XII. continued.
Gene SNP Serum LdL-cholesterol (mmol/l) P-value
LOC105375015 rs9264942 T/C TT TC CC 0.0001
   3.13±0.84 3.15±0.87 3.25±0.88 
ZSCAN31 rs6922302 C/G CC CG GG <0.0001
   3.14±0.85 3.24±0.90 3.37±0.85 
MDC1 rs2269702 A/G AA AG GG 0.0013
   3.14±0.85 3.20±0.87 3.28±0.91 
MDC1 rs28986465 C/T CC CT TT 0.0013
   3.14±0.85 3.20±0.87 3.28±0.91 
MDC1 rs2075015 G/A GG GA AA 0.0013
   3.14±0.85 3.20±0.87 3.28±0.91 
DHX16 rs2285321 T/c TT Tc cc 0.0011
   3.14±0.85 3.20±0.87 3.28±0.91 
SKIV2L rs492899 A/G AA AG GG 0.0001
   3.14±0.85 3.23±0.89 3.36±0.91 
MDC1 rs6924270 A/G AA AG GG 0.0012
   3.14±0.85 3.20±0.87 3.28±0.91 
 rs2508015 c/T cc cT TT 0.0005
   3.14±0.85 3.22±0.88 3.31±0.86 
TUBB rs25527 c/T cc cT TT 0.0008
   3.14±0.86 3.19±0.86 3.27±0.89 
PPP1R18 rs9468805 G/A GG GA AA 0.0016
   3.14±0.85 3.20±0.87 3.28±0.91 
DHX16 rs6937357 T/C TT TC CC 0.0016
   3.14±0.85 3.20±0.87 3.28±0.91 
HECTD4 rs11066280 T/A TT TA AA 0.0005
   3.12±0.88 3.19±0.85 3.24±0.81 
TRIM40 rs2523995 G/A GG GA AA 0.0008
   3.14±0.85 3.22±0.89 3.32±0.87 
PPP1R18 rs6457254 C/T CC CT TT 0.0010
   3.14±0.85 3.20±0.87 3.28±0.91 
TUBB rs3132584 c/A cc cA AA 0.0008
   3.13±0.86 3.19±0.86 3.27±0.90 
 rs3130685 T/C TT TC CC 0.0234
   3.20±0.89 3.14±0.84 3.14±0.85 
GIT2 rs2292354 c/T cc cT TT 0.0077
   3.18±0.86 3.15±0.87 3.05±0.82 
PPP1R18 rs2394392 T/G TT TG GG 0.0013
   3.14±0.85 3.20±0.87 3.28±0.91 
 rs2524272 T/c TT Tc cc 0.0005
   3.13±0.86 3.18±0.87 3.27±0.87 
data are presented as mean ± standard deviation and were compared among genotypes by one-way analysis of variance. Based on Bonferroni's 
correction, P<0.0008 (0.05/65) was considered statistically significant (indicated in bold). SNP, single nucleotide polymorphism; LDL, low 
density lipoprotein.
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to predict functional gene-gene interactions, with the use of 
the GeneMANIA cytoscape plugin (http://apps.cytoscape.
org/apps/genemania; donnelly centre for cellular and 
Biomolecular Research, University of Toronto, Toronto, 
canada) (35-37) and cytoscape v3.4.0 sof tware 
(http://www.cytoscape.org; The cytoscape consortium, San 
diego, cA, USA) (38). Given that LOC105375015 protein 
has not been characterized, it was not examined. A set of 50 
dyslipidemia-related genes were selected from the disGeNET 
database (ht tp://www.disgenet.org/web/disGeNET; 
Integrative Biomedical Informatics Group, Research 
Programme on Biomedical Informatics, Barcelona Biomedical 
Research Park, Barcelona, Spain) (39,40) according to the rank 
order (high to low) of scores for association with dyslipidemia. 
The network analysis revealed that the 10 or three genes asso-
ciated in the present study with hypo-HdL-cholesterolemia 
or hyper-LdL-cholesterolemia, respectively, have potential 
direct or indirect interactions with the 50 genes previously 
demonstrated to be associated with dyslipidemia (Fig. 5).
Discussion
dyslipidemia is an important public health problem because 
of its high prevalence and role as a risk factor for more serious 
conditions, including coronary artery disease, ischemic stroke, 
and colorectal cancer (9-12). The identification of genetic 
variants that confer susceptibility to dyslipidemia is thus clini-
cally important for prevention of these conditions. The present 
study has performed novel EWASs for hypertriglyceridemia, 
hypo-HdL-cholesterolemia, and hyper-LdL-cholesterolemia 
in subjects with early-onset forms of these disorders, which 
may have a greater genetic component compared with 
late-onset forms.
Among 25 SNPs in six genes and five chromosomal loci 
significantly associated with early‑onset hypertriglyceridemia, 
the present study newly identified rs11085421 at 19p12 as a 
susceptibility locus for this condition. This SNP was signifi-
cantly associated with serum triglyceride concentration, with the 
minor C allele being protective against hypertriglyceridemia.
Figure 3. LD map for five SNPs at chromosomal region 12q24.12 to 12q24.13 associated with hypo‑HDL‑cholesterolemia. LD was calculated as the square of 
the correlation coefficient (r2), with the extent of Ld increasing according to the color order of gray to red. Ld, linkage disequilibrium; SNP, single nucleotide 
polymorphism.
Figure 4. LD map for 47 SNPs at 6p22.3 to 6p21.3 associated with hyper‑LDL‑cholesterolemia. LD was calculated as the square of the correlation coefficient 
(r2), with the extent of Ld increasing according to the color order of blue to gray to red. Ld, linkage disequilibrium; SNP, single nucleotide polymorphism.
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Among 28 SNPs in 24 genes and two chromosomal loci 
significantly associated with hypo‑HDL‑cholesterolemia, the 
current study newly identified 13 genes (MOB3C, TMOD4, 
LPGAT1, EHD3, SPOPL, COL6A3, ZNF860, CACNA1D, 
COL6A5, ADGRL3, DCLRE1C, OR4F6, ZNF77 ) as 
potential susceptibility loci for this condition. SNPs of 12 
of these genes were significantly associated with serum 
HdL-cholesterol levels, with minor alleles of LPGAT1, 
EHD3, ZNF860, CACNA1D, and DCLRE1C representing 
risk factors for hypo-HdL-cholesterolemia and minor alleles 
of MOB3C, TMOD4, COL6A3, COL6A5, ADGRL3, OR4F6, 
and ZNF77 being protective against this condition. Given 
that rs114501427 of SPOPL was not significantly related 
to serum HdL-cholesterol concentration, this gene was 
excluded as a novel susceptibility locus. Furthermore, given 
that significant LD was apparent among SNPs of ADGRL3, 
CXCL8, and MARCH1, as well as between SNPs of OR4F6 
and VPS33B, ADGRL3 and OR4F6 were also removed from 
the final list of novel significant loci. In addition, significant 
Ld was detected between SNPs of MOB3C and TMOD4 
as well as between those of ZNF860 and CACNA1D. 
We thus identified eight novel loci (MOB3C‑TMOD4, 
LPGAT1, EHD3, COL6A3, ZNF860‑CACNA1D, COL6A5, 
DCLRE1C, ZNF77) that confer susceptibility to early-onset 
hypo-HdL-cholesterolemia.
Among 65 SNPs in 44 genes and two chromosomal loci 
significantly associated with hyper‑LDL‑cholesterolemia, 
the present study newly identified 16 genes (PTCH2, 
MOB3C, TMOD4, COL6A3, COL6A5, ADGRL3, KIAA0319, 
FAM65B, ZSCAN26, UBD, DHX16, LOC105375015, NEU1, 
MUC17, GIT2, ZNF77) as potential susceptibility loci 
for this condition. SNPs of six of these genes (KIAA0319, 
FAM65B, ZSCAN26, UBD, LOC105375015, NEU1) were 
significantly associated with serum LDL‑cholesterol levels, 
with minor alleles of these genes representing risk factors for 
hyper-LdL-cholesterolemia. Given that SNPs of 10 genes 
(PTCH2, MOB3C, TMOD4, COL6A3, COL6A5, ADGRL3, 
DHX16, MUC17, GIT2, ZNF77) were not significantly 
related to the serum LdL-cholesterol concentration, these 
genes were removed from the list of novel susceptibility 
loci, even though this discrepancy may be attributable to 
the effects of lipid-lowering medication. Given that rs13118 
of NEU1 was in significant LD with rs492899 of SKIV2L 
in a large Ld block and that rs76463649 of ZSCAN26 was 
in Ld with SNPs of SLC17A3, ZSCAN31, GABBR1, and 
TRIM40, both NEU1 and ZSCAN26 were also excluded 
from the final results. In addition, significant Ld was 
detected between SNPs of KIAA0319 and FAM65B. We 
thus identified three novel loci (KIAA0319‑FAM65B, UBD, 
LOC105375015) that confer susceptibility to early-onset 
hyper-LdL-cholesterolemia.
A recent study has reported that network analysis of 
functional gene-gene interactions may be informative with 
regard both to clarification of biological processes under-
lying coronary artery disease and to the identification of 
therapeutic targets for this condition (41). A network analysis 
was therefore performed in the present study in order to 
predict biological processes related to the identified genes 
and the interactions of these genes with those previously 
known to be associated with dyslipidemia. The results from 
the network analysis revealed that the 10 or three genes asso-
ciated in the present study with hypo-HdL-cholesterolemia 
or hyper-LdL-cholesterolemia respectively, had direct or 
indirect interactions with the 50 dyslipidemia-related genes 
selected from the disGeNET database (39,40). The under-
lying molecular mechanisms of these interactions, however, 
remain to be elucidated.
Our group has previously reported that two, three and 
nine SNPs were associated with hypertriglyceridemia 
(P<1.71x10-4), hypo‑HDL‑cholesterolemia (P<1.44x10 -4), 
Figure 5. Network analysis of the genes identified in the present study with known dyslipidemia‑related genes. The 10 genes (MOB3C, TMOD4, LPGAT1, 
EHD3, COL6A3, ZNF860, CACNA1D, COL6A5, DCLRE1C, ZNF77) and three genes (KIAA0319, FAM65B, UBD) associated in the present study with 
hypo-HdL-cholesterolemia and hyper-LdL-cholesterolemia, respectively, are indicated in red circles. The 50 dyslipidemia-related genes selected from the 
disGeNET database (http://www.disgenet.org/ web/ disGeNET) are indicated in green circles. Interactions between red circles or between red and green 
circles are indicated by bold lines. Molecules represented by gray circles are putative mediators of interactions between the genes.
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and hyper‑LDL‑cholesterolemia (P<1.10x10-4), respectively, 
as determined by multivariable logistic regression analysis 
with adjustment for age and sex, following an initial EWAS 
screening of allele frequencies among subjects with early- or 
late-onset forms of these conditions (28). The associations 
of the two SNPs [rs10790162 (P=3.58x10-24) and rs7350481 
(P=7.94x10-23)] with hypertriglyceridemia were replicated 
(P<0.05) in the present study. The associations of two of 
the three SNPs [rs147317864 (P=0.0139) and rs12229654 
(P=0.0001)] with hypo‑HDL‑cholesterolemia were repli-
cated in the present study. The associations of eight of the nine 
SNPs [rs7771335 (P=1.00x10 -7), rs2071653 (P=1.61x10 -5), 
rs2853969 (P=6.16x10 -8), rs2269704 (P=2.92x10 -7), 
r s2269703 ( P=3.67x10 -7),  r s495089 ( P= 0.0 0 01), 
rs2269702 (P=5.13x10-7) and rs1233399 (P=0.0009)] with 
hyper-LdL-cholesterolemia were replicated in the present 
study. Although the association of most SNPs with dyslip-
idemia identified in our previous study (28) was replicated, 
genetic variants associated with hypertriglyceridemia, 
hypo-HdL-cholesterolemia, or hyper-LdL-cholesterolemia 
appear to differ, at least in part, between early- and late-onset 
forms of the diseases.
Table XIV. Relation of genes, chromosomal loci and SNPs associated with hypo-HdL-cholesterolemia in the present study to 
previously examined dyslipidemia-related phenotypes.
Gene/chr locus SNP chr Position Previously examined phenotypes
MOB3C rs139537100 1 46615006 None
TMOD4 rs115287176 1 151170961 None
LPGAT1 rs150552771 1 211783358 None
EHD3 rs116417209 2 31249417 None
SPOPL rs114501427 2 138568946 None
COL6A3 rs146092501 2 237371861 None
ZNF860 rs140232911 3 31989561 None
CACNA1D rs35874056 3 53702798 None
COL6A5 rs200982668 3 130470894 None
ADGRL3 rs192210727 4 61909615 None
CXCL8 rs188378669 4 73741568 Total cholesterol (23063622)
MARCH1 rs61734696 4 164197303 Adiponectin concentrations (20887962)
6p22.1 rs9261800 6 30408822 Type 1 diabetes (17554300)
DCLRE1C rs150854849 10 14934704 None
APOA5 rs2075291 11 116790676  HDL‑cholesterol (23063622, 20686565, 22629316, 
21386085)
BRAP rs3782886 12 111672685 HDL‑cholesterol (21572416)
ACAD10 rs11066015 12 111730205 LDL‑cholesterol (20686565)
ALDH2 rs671 12 111803962 HDL‑cholesterol (21572416)
HECTD4 rs2074356 12 112207597  HDL‑cholesterol (21572416, 21909109, 
    22751097)
 rs11066280 12 112379979 
PLCB2 rs200787930 15 40289298 Triglycerides (23063622)
VPS33B rs199921354 15 91013841 Type 2 diabetes (22885922)
OR4F6 rs141569282 15 101806068 None
16q13 rs247616 16 56955678  HDL‑cholesterol (20686565, 19060906, 20339536, 
20838585, 19060911, 20031538)
16q13 rs3764261 16 56959412  HDL‑cholesterol (20686565, 23063622, 19060911, 
21943158, 21347282, 18193043, 20694148, 
21589926, 19802338, 19913121)
CETP rs1532624 16 56971567  HDL‑cholesterol (20686565, 23063622, 22629316, 
    21347282, 21589926, 19060911, 20031564, 
    19060906, 18193044, 21943158)
ZNF77 rs146879198 19 2934109 None
LILRB2 rs73055442 19 54279838 HDL‑cholesterol (20686565)
data were obtained from the Genome-Wide Repository of Associations Between SNPs and Phenotypes (GRASP) Search database (https://grasp.
nhlbi.nih.gov/Search.aspx) with a P‑value of <1.0x10‑6. Numbers in parentheses are PubMed Ids. SNP, single nucleotide polymorphism; chr, 
chromosome.
INTERNATIONAL JOURNAL OF MOLEcULAR MEdIcINE  43:  57-82,  2019 79
Table XV. Relation of genes, chromosomal loci and SNPs associated with hyper-LdL-cholesterolemia in the present study to 
previously examined dyslipidemia-related phenotypes.
Gene/chr locus SNP chr Position Previously examined phenotypes
PTCH2 rs147284320 1 44828589 None
MOB3C rs139537100 1 46615006 None
PCSK9 rs151193009 1 55043912  LDL‑cholesterol (23063622, 21347282, 18193044, 
20686565, 22629316)
TMOD4 rs115287176 1 151170961 None
APOB rs13306206 2 21019859 LDL‑cholesterol (20686565, 23202125, 23063622)
COL6A3 rs146092501 2 237371861 None
COL6A5 rs200982668 3 130470894 None
ADGRL3 rs192210727 4 61909615 None
CXCL8 rs188378669 4 73741568 Total cholesterol (23063622)
MARCH1 rs61734696 4 164197303 Adiponectin concentrations (20887962)
KIAA0319 rs4576240 6 24596250 None
FAM65B rs150142878 6 24847657 None
SLC17A3 rs34902660 6 25850874 Serum urate (23263486), type 1 diabetes (17554300)
ZSCAN26 rs76463649 6 28271963 None
ZSCAN31 rs6922302 6 28327533 Type 1 diabetes (17554300)
UBD rs64036 6 29559490 None
GABBR1 rs29243 6 29631325 Type 1 diabetes (17554300)
6p22.1 rs2524272 6 29714623 Type 1 diabetes (17554300)
TRIM40 rs2523995 6 30134407 Type 1 diabetes (17554300, 17632545)
DHX16 rs7749235 6 30667816 None
 rs2285321 6 30670221 
 rs6937357 6 30672547 
PPP1R18 rs9468805 6 30675932 Type 1 diabetes (17632545)
 rs6457254 6 30681357 
 rs2394392 6 30682541 
6p21.3 rs3130663 6 30698817 Type 1 diabetes (17632545, 17554300)
MDC1 rs2269702 6 30707358  Fat mass (19584900), type 1 diabetes (17554300), body 
mass index (19584900)
 rs28986465 6 30712785 
 rs2075015 6 30712831 
 rs6924270 6 30714203 
TUBB rs3132584 6 30720650 Type 1 diabetes (17554300)
 rs25527 6 30723161 
 rs9500864 6 30725455 
DPCR1 rs6933400 6 30939399 Type 1 diabetes (17554300, 17632545)
 rs11970154 6 30952101 
6p21.3 rs2508015 6 31042423 Type 1 diabetes (17632545), triglycerides (20686565)
CCHCR1 rs147733073 6 31145462 Triglycerides (20686565)
6p21.3 rs3130685 6 31238429 Triglycerides (20686565), type 1 diabetes (17554300)
LOC105375015 rs9264942 6 31306603 None
6p21.3 rs2596574 6 31366397  LDL‑cholesterol (23063622), total cholesterol 
(23063622), type 1 diabetes (17554300, 17632545)
PRRC2A rs11538264 6 31635412  Type 1 diabetes (17554300, 17632545), triglycerides 
(20686565), total cholesterol (20686565)
LY6G6F rs9267546 6 31705659 Triglycerides (20686565)
 rs17200983 6 31707506 
 rs9267547 6 31707724 
LY6G6C rs117894946 6 31719250 Type 1 diabetes (17554300, 17632545)
MSH5 rs11754464 6 31755958  Type 1 diabetes (17554300, 17632545), triglycerides 
(20686565), total cholesterol (20686565)
YAMAdA et al:  EXOME-WIdE ANALYSIS OF dYSLIPIdEMIA80
There are several limitations to the present study. Firstly, 
given that the results were not replicated, their validation 
will be necessary in independent study populations or in 
other ethnic groups. The identified SNPs were not tested 
in a clinical setting to validate the assessment of genetic 
risk for dyslipidemia in patients. In addition, it is possible 
that SNPs identified in the present study may be in Ld 
with other genetic variants in the same gene or in nearby 
genes that are actually responsible for the development 
of hypertriglyceridemia, hypo-HdL-cholesterolemia, or 
hyper-LdL-cholesterolemia. Finally, the functional relevance 
of identified SNPs to the pathogenesis of hypertriglyceridemia, 
hypo-HdL-cholesterolemia, or hyper-LdL-cholesterolemia 
remains to be elucidated.
In conclusion, the present study has identified chromo-
some 19p12, eight loci (MOB3C‑TMOD4, LPGAT1, EHD3, 
COL6A3, ZNF860‑CACNA1D, COL6A5, DCLRE1C, ZNF77) 
and three loci (KIAA0319‑FAM65B, UBD, LOC105375015) 
that confer susceptibility to early-onset hypertriglyceridemia, 
hypo-HdL-cholesterolemia and hyper-LdL-cholesterolemia, 
respectively. determination of genotypes for the SNPs at 
these loci may prove informative for assessment of genetic 
risk for hypertriglyceridemia, hypo-HdL-cholesterolemia and 
hyper-LdL-cholesterolemia in the Japanese population.
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